| |
3-MU group, No. (%)
|
6-MU group, No. (%)
|
P value
|
|---|
|
Patient number
|
80
|
134
| |
|
Discontinuation
|
4 (5.0)
|
10 (7.5)
|
NS
|
|
Adverse event
|
3 (3.8)
|
6 (4.5)
|
NS
|
|
Insufficient response
|
1 (1.3)
|
1 (0.7)
|
NS
|
|
Laboratory abnormality
|
0 (0)
|
1 (0.7)
|
NS
|
|
Economic problem
|
0 (0)
|
2 (1.5)
|
NS
|
|
Adverse event
| | | |
|
Flu-like symptoms†
|
49 (61.3)
|
85 (63.4)
|
NS
|
|
Gastrointestinal manifestations‡
|
19 (23.8)
|
35 (26.1)
|
NS
|
|
Psychological manifestations§
|
34 (41.0)
|
74 (55.2)
|
0.028
|
|
Alopecia
|
13 (16.3)
|
30 (22.4)
|
NS
|
|
Dermatological manifestations¶
|
11 (13.8)
|
19 (14.2)
|
NS
|
- Note: 3-MU group: interferon-α 3 million units thrice weekly for 24 weeks.
- 6-MU group: interferon-α 6 million units thrice weekly for 24 weeks.
- NS: not significant.
- † Including fatigue, headache, pyrexia, myalgia, and rigors.
- ‡ Including nausea, vomiting, anorexia, and diarrhea.
- §Including irritability, depression, and insomnia.
- ¶Including dermatitis, and pruritus.
